SCHEMBL286003

SCHEMBL286003

CCCNC(=O)c1cc(C=Cc2c(-c3ccc(F)cc3)noc2C)n[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
HDAC6 Q9UBN7 11/20 0.43
HDAC3 O15379 10/20 0.43
HDAC4 P56524 10/20 0.43
HDAC1 Q13547 10/20 0.43
HDAC7 Q8WUI4 10/20 0.43
HDAC2 Q92769 10/20 0.43
HDAC10 Q969S8 10/20 0.43
HDAC11 Q96DB2 10/20 0.43
HDAC8 Q9BY41 10/20 0.43
HDAC9 Q9UKV0 10/20 0.43
HDAC5 Q9UQL6 10/20 0.43
NCOR2 Q9Y618 5/20 0.42
TP53 P04637 2/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL286279 0.92 KDM4E (0.45) KDM4EHDAC6HDAC3HDAC4HDAC1
SCHEMBL286278 0.92 KDM4E (0.45) KDM4EHDAC6HDAC3HDAC4HDAC1
SCHEMBL286178 0.90 HDAC6 (0.46) KDM4EHDAC6HDAC3HDAC4HDAC1
SCHEMBL286192 0.88 GABRA5 (0.49) KDM4EHDAC6HDAC3HDAC4HDAC1
SCHEMBL286299 0.87 KDM4E (0.43) KDM4EHDAC6HDAC3HDAC4HDAC1
SCHEMBL286004 0.85 GABRA5 (0.46) KDM4ELMNAHTTALPLGAA
SCHEMBL286002 0.85 GABRA5 (0.46) KDM4ELMNAHTTALPLGAA
SCHEMBL2098868 0.84 KDM4E (0.43) KDM4EHDAC6HDAC3HDAC4HDAC1
SCHEMBL285881 0.84 KDM4E (0.43) KDM4ETP53NPC1LMNARAB9A
SCHEMBL286110 0.84 ALPL (0.48) KDM4ELMNAALPLGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163728-B2 Pyrazoles HOFFMANN-LA ROCHE INC. (US) 2012-04-24 US claimed
US-20100286115-A1 PYRAZOLES ROCHE PALO ALTO LLC 2010-11-11 US claimed
US-8163728-B2 Pyrazoles HOFFMANN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2427455-A1 ISOXAZOLE-PYRAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010127975-A1 ISOXAZOLE-PYRAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286115-A1 PYRAZOLES ROCHE PALO ALTO LLC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286115-A1 PYRAZOLES GABRA5, GABRA1, GABRA3 KDM4E 2372/4885HDAC6 1589/4885HDAC3 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.